Clinical trials are the backbone of all drug development. It is important, but also expensive and associated with many challenges and high risks. Both Public Research Organisations (PROs), their TTOs and the industry are familiar with this.
The future of smaller cohorts related to the anticipated drive towards personalized medicine introduces even further challenges. In this session, we will discuss how this work can be organized and what the implications of the new needs are.
Moderator: Anette Poulsen Miltoft, Head of Corporate Relations and Technology Transfer, Aarhus University, Denmark